MA50041A - Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci - Google Patents

Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci

Info

Publication number
MA50041A
MA50041A MA050041A MA50041A MA50041A MA 50041 A MA50041 A MA 50041A MA 050041 A MA050041 A MA 050041A MA 50041 A MA50041 A MA 50041A MA 50041 A MA50041 A MA 50041A
Authority
MA
Morocco
Prior art keywords
preparation
methods
same
spirocyclic compounds
spirocyclic
Prior art date
Application number
MA050041A
Other languages
English (en)
Inventor
Daniel J Buzard
Cheryl A Grice
Todd K Jones
Michael B Shaghafi
Olivia D Weber
Original Assignee
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck La Jolla Research Center Inc filed Critical Lundbeck La Jolla Research Center Inc
Publication of MA50041A publication Critical patent/MA50041A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MA050041A 2017-08-29 2018-08-28 Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci MA50041A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762551721P 2017-08-29 2017-08-29

Publications (1)

Publication Number Publication Date
MA50041A true MA50041A (fr) 2020-07-08

Family

ID=65527860

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050041A MA50041A (fr) 2017-08-29 2018-08-28 Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci

Country Status (27)

Country Link
US (1) US11142526B2 (fr)
EP (1) EP3675847B1 (fr)
JP (1) JP7257387B2 (fr)
KR (1) KR20200046061A (fr)
CN (1) CN111050765B (fr)
AU (1) AU2018323459A1 (fr)
BR (1) BR112020004101A2 (fr)
CA (1) CA3072923A1 (fr)
CL (1) CL2020000462A1 (fr)
CO (1) CO2020001724A2 (fr)
CR (1) CR20200089A (fr)
DO (1) DOP2020000039A (fr)
EA (1) EA202090312A1 (fr)
EC (1) ECSP20013337A (fr)
ES (1) ES2952332T3 (fr)
GE (2) GEP20217327B (fr)
IL (1) IL272580B (fr)
JO (1) JOP20200023A1 (fr)
MA (1) MA50041A (fr)
MX (1) MX2020002251A (fr)
NI (1) NI202000014A (fr)
PE (1) PE20200664A1 (fr)
PH (1) PH12020500372A1 (fr)
SG (1) SG11202001022TA (fr)
UA (1) UA126685C2 (fr)
WO (1) WO2019046318A1 (fr)
ZA (1) ZA202001208B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2793148T3 (es) 2012-01-06 2020-11-13 Lundbeck La Jolla Research Center Inc Compuestos de carbamato y métodos para fabricarlos y usarlos
ES2861648T3 (es) 2016-05-12 2021-10-06 Lundbeck La Jolla Research Center Inc Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CA3072923A1 (fr) 2017-08-29 2019-03-07 Lundbeck La Jolla Research Center, Inc. Composes spirocycliques et procedes de preparation et d'utilisation de ceux-ci
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
JP7649283B2 (ja) * 2019-07-09 2025-03-19 エフ. ホフマン-ラ ロシュ アーゲー 新規複素環化合物
WO2022043284A1 (fr) * 2020-08-26 2022-03-03 F. Hoffmann-La Roche Ag Composés hétérocycliques utiles en tant qu'inhibiteurs de magl
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商H 朗德貝克公司 Magl抑制劑
CA3242372A1 (fr) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibition de la monoacylglycerol lipase (magl)
AU2023264787A1 (en) 2022-05-04 2024-10-31 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.
EP4665718A1 (fr) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Petites molécules utilisées en tant qu'inhibiteurs de monoacylglycérol lipase (magl), compositions et utilisation associées

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440803A1 (fr) 2001-03-07 2002-09-12 Pfizer Products Inc. Modulateurs de l'activite du recepteur de la chimiokine
JPWO2008023720A1 (ja) 2006-08-23 2010-01-14 アステラス製薬株式会社 ウレア化合物又はその塩
US20110071180A1 (en) 2008-03-05 2011-03-24 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
US8575296B2 (en) 2009-09-29 2013-11-05 Polyone Corporation Polyester articles having simulated metallic or pearlescent appearance
MX2012004753A (es) 2009-10-23 2012-09-07 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina.
AU2011223898A1 (en) 2010-03-04 2012-09-13 Merck Sharp & Dohme Corp. Positive allosteric modulators of mGluR2
FR2960875B1 (fr) * 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (fr) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Utilisation d'inhibiteurs de PI3K pour le traitement de l'obésité
ES2793148T3 (es) 2012-01-06 2020-11-13 Lundbeck La Jolla Research Center Inc Compuestos de carbamato y métodos para fabricarlos y usarlos
BR112015004111A2 (pt) 2012-09-25 2017-07-04 Hoffmann La Roche novos derivados bicíclicos
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター,インク. ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
WO2015179559A2 (fr) * 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
CA2979537C (fr) 2015-03-18 2023-08-29 Abide Therapeutics, Inc. Carbamates de piperazine et procedes de preparation et d'utilisation de ceux-ci
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
EA036637B1 (ru) 2016-03-31 2020-12-02 Такеда Фармасьютикал Компани Лимитед Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу
ES2861648T3 (es) 2016-05-12 2021-10-06 Lundbeck La Jolla Research Center Inc Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos
JOP20190050A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
EP3541807B1 (fr) 2016-11-16 2021-09-29 H. Lundbeck A/S Une forme cristalline d'un inhibiteur de magl
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CA3072923A1 (fr) 2017-08-29 2019-03-07 Lundbeck La Jolla Research Center, Inc. Composes spirocycliques et procedes de preparation et d'utilisation de ceux-ci
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso

Also Published As

Publication number Publication date
ES2952332T3 (es) 2023-10-30
CL2020000462A1 (es) 2020-07-10
ZA202001208B (en) 2021-08-25
IL272580A (en) 2020-03-31
RU2020107163A (ru) 2021-09-30
AU2018323459A1 (en) 2020-02-20
JP7257387B2 (ja) 2023-04-13
CA3072923A1 (fr) 2019-03-07
EA202090312A1 (ru) 2020-08-05
US20200255427A1 (en) 2020-08-13
US11142526B2 (en) 2021-10-12
WO2019046318A1 (fr) 2019-03-07
GEAP202115281A (en) 2021-08-10
JOP20200023A1 (ar) 2020-02-02
RU2020107163A3 (fr) 2022-03-15
CN111050765A (zh) 2020-04-21
CR20200089A (es) 2020-04-08
CN111050765B (zh) 2024-01-02
EP3675847C0 (fr) 2023-07-12
IL272580B (en) 2022-09-01
SG11202001022TA (en) 2020-03-30
EP3675847A4 (fr) 2021-01-06
PH12020500372A1 (en) 2020-12-07
UA126685C2 (uk) 2023-01-11
DOP2020000039A (es) 2020-08-31
GEP20217327B (en) 2021-12-10
MX2020002251A (es) 2020-07-20
NI202000014A (es) 2020-07-28
EP3675847B1 (fr) 2023-07-12
ECSP20013337A (es) 2020-04-22
PE20200664A1 (es) 2020-06-11
BR112020004101A2 (pt) 2020-09-24
EP3675847A1 (fr) 2020-07-08
CO2020001724A2 (es) 2020-02-28
KR20200046061A (ko) 2020-05-06
JP2020532545A (ja) 2020-11-12

Similar Documents

Publication Publication Date Title
EP3675848A4 (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA50041A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3370715A4 (fr) Composés chimères de ciblage de protéolyse et procédés de préparation et d'utilisation de ceux-ci
EP3455226A4 (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3704239A4 (fr) Compositions de casz et procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3504213A4 (fr) Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
EP3429635A4 (fr) Composés anti-crispr et leurs procédés d'utilisation
EP3504251A4 (fr) Polymères réticulés et procédés de préparation et d'utilisation de ceux-ci
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA49752A (fr) Procédés de préparation de composés de pyrrolidine
MA52492A (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
EP3778607C0 (fr) Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
EP3271352A4 (fr) Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci
EP3504196A4 (fr) Procédés de préparation d'olaparib
EP3645049A4 (fr) Anticorps multispécifiques et procédés de préparation et d'utilisation associés
MA44611A (fr) Compositions de composés hydrophobes cristallisés et leurs procédés de préparation et d'utilisation
MA49560A (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
EP3526205A4 (fr) Composés thérapeutiques et leurs procédés d'utilisation
EP3429754A4 (fr) Cartouches de préparation d'échantillons et leurs procédés d'utilisation
EP3662007A4 (fr) Agents de matité à base de silice et procédés de préparation et d'utilisation desdits agents
EP3349755A4 (fr) Formulations de nicotine, leurs procédés de préparation et d'utilisation
EP3350196A4 (fr) Composés carborane et leurs procédés d'utilisation